The U.S. Food and Drug Administration has approved an expanded indication for Merck's (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE